CA2426069A1 - Treatment of anxiety disorders - Google Patents

Treatment of anxiety disorders Download PDF

Info

Publication number
CA2426069A1
CA2426069A1 CA002426069A CA2426069A CA2426069A1 CA 2426069 A1 CA2426069 A1 CA 2426069A1 CA 002426069 A CA002426069 A CA 002426069A CA 2426069 A CA2426069 A CA 2426069A CA 2426069 A1 CA2426069 A1 CA 2426069A1
Authority
CA
Canada
Prior art keywords
norepinephrine reuptake
reuptake inhibitor
dsm
disorder
anxiety disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002426069A
Other languages
English (en)
French (fr)
Inventor
David Michelson
Holly Ann Read
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2426069A1 publication Critical patent/CA2426069A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002426069A 2000-11-15 2001-11-06 Treatment of anxiety disorders Abandoned CA2426069A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US60/249,010 2000-11-15
US26536201P 2001-01-31 2001-01-31
US60/265,362 2001-01-31
PCT/US2001/027801 WO2002040006A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Publications (1)

Publication Number Publication Date
CA2426069A1 true CA2426069A1 (en) 2002-05-23

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002426069A Abandoned CA2426069A1 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Country Status (16)

Country Link
EP (1) EP1395253A2 (pt)
JP (1) JP2004529073A (pt)
KR (1) KR20030051812A (pt)
CN (1) CN1822825A (pt)
AU (1) AU2002217757A1 (pt)
BR (1) BR0115301A (pt)
CA (1) CA2426069A1 (pt)
CZ (1) CZ20031339A3 (pt)
EA (1) EA200300567A1 (pt)
HR (1) HRP20030384A2 (pt)
IL (1) IL155874A0 (pt)
MX (1) MXPA03004190A (pt)
NO (1) NO20032156D0 (pt)
PL (1) PL366119A1 (pt)
SK (1) SK5422003A3 (pt)
WO (1) WO2002040006A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032380A3 (en) * 2001-03-06 2004-03-17 Eli Lilly And Company Inhibitor of monoamine uptake
CN1674907A (zh) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 瑞波西汀在治疗热潮红中的用途
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2009089479A2 (en) 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
JP2022519541A (ja) * 2019-02-01 2022-03-24 ホフマン・テクノロジーズ・エルエルシー 不安関連障害を処置するための組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2931997A (en) * 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
ES2246485T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la incontinencia.

Also Published As

Publication number Publication date
IL155874A0 (en) 2003-12-23
CZ20031339A3 (cs) 2003-10-15
CN1822825A (zh) 2006-08-23
NO20032156L (no) 2003-05-13
WO2002040006A3 (en) 2003-12-24
AU2002217757A1 (en) 2002-05-27
JP2004529073A (ja) 2004-09-24
MXPA03004190A (es) 2003-09-22
HRP20030384A2 (en) 2003-08-31
BR0115301A (pt) 2004-12-14
WO2002040006A2 (en) 2002-05-23
EA200300567A1 (ru) 2004-10-28
EP1395253A2 (en) 2004-03-10
KR20030051812A (ko) 2003-06-25
NO20032156D0 (no) 2003-05-13
PL366119A1 (en) 2005-01-24
SK5422003A3 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
CA2304657C (en) Treatment of conduct disorder
US6028070A (en) Treatment of oppositional defiant disorder
Gillin et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial
RU2488392C2 (ru) Лечение агонистом мелатонина
CA2426069A1 (en) Treatment of anxiety disorders
US20080200555A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
US6683114B2 (en) Treatment of psoriasis
TW200300672A (en) Treatment of cognitive failure
US20040034106A1 (en) Treatment of anxiety disorders
ZA200303738B (en) Treatment of anxiety disorders.
US4443479A (en) Pharmaceutical methods and compositions using parabenzoquinone
MXPA00002837A (en) Treatment of oppositional defiant disorder
MXPA00002829A (en) Treatment of conduct disorder

Legal Events

Date Code Title Description
FZDE Discontinued